Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of EDP1815 versus placebo in mild to severe atopic dermatitis
2021-001805-63Phase 2Completed
- Sponsor
- Evelo Biosciences
- Start
- Aug 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing EDP1815 with Placebo (2 arms). Primary endpoint: Achievement of EASI-50 response at Week 16. Started Aug 2021; status: completed.
02
Drugs
EDP1815
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-001805-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001805-63.